# A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

Source: https://onco.cc/trials/nct05579132/  
OnCo record `nct05579132` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MK-1045 in acute lymphoblastic leukaemia, run by MSD R&D (China) Co., Ltd., now recruiting.

## Summary

A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) is a phase 1/2 interventional study registered as NCT05579132 by MSD R&D (China) Co., Ltd., with 203 participants planned, started 2022-11-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: MK-1045.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05579132
- Phase: 1/2
- Setting: An Open-label, Multi-center Phase Ib/II Study of MK-1045 (CN201) in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia
- Sponsor: MSD R&D (China) Co., Ltd.
- Enrolled: 203

## Sources

- ClinicalTrials.gov NCT05579132: https://clinicaltrials.gov/study/NCT05579132

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [MK-1045](https://onco.cc/drugs/mk-1045/)

---
JSON: https://onco.cc/api/v1/entities/nct05579132.json